Indomethacin Sodium

CHEMBL3989410 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
379.8 g/mol
LogP
Phase
4

This sodium salt of indomethacin is the intravenous formulation used primarily in neonatal medicine to close patent ductus arteriosus, an abnormal blood vessel connection near the heart that should close after birth. Like the oral form, it inhibits prostaglandin synthesis through COX inhibition. The injectable form provides rapid systemic effects.

Khối lượng phân tử

379,8000 g/mol

TPSA

71,40 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]

InChI

InChI=1S/C19H16ClNO4.Na.3H2O/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;;;;/h3-9H,10H2,1-2H3,(H,22,23);;3*1H2/q;+1;;;/p-1

Molecular Formula

C19H15ClNNaO4

HBD / HBA

- / 4

Liên kết có thể quay

4

Nguyên tử nặng

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This sodium salt of indomethacin is the intravenous formulation used primarily in neonatal medicine to close patent ductus arteriosus, an abnormal blood vessel connection near the heart that should close after birth. Like the oral form, it inhibits prostaglandin synthesis through COX inhibition. The injectable form provides rapid systemic effects.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Indomethacin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989410. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23675763. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.